News | April 28, 2025
Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Subscribe To Our Newsletter & Stay Updated
